Trial Profile
A phase I/II of S-222611 combined with trastuzumab +/- chemotherapy in patients with HER2-positive metastatic breast cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 29 Jun 2020
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Epertinib (Primary) ; Trastuzumab (Primary) ; Trastuzumab (Primary) ; Vinorelbine (Primary)
- Indications Advanced breast cancer; Brain metastases; Male breast cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use